Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News aTyr Pharma Inc ATYR

Healthcare Biotechnology
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause... see more

Recent & Breaking News (NDAQ:ATYR)

aTyr Pharma Presents Preclinical Research Characterizing Effects of ATYR2810 in Highly Aggressive Tumor Subtypes at the 2022 AACR Annual Meeting

GlobeNewswire April 11, 2022

aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference

GlobeNewswire April 1, 2022

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 25, 2022

 aTyr Pharma Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update

GlobeNewswire March 14, 2022

aTyr Pharma Announces Positive End-of-Phase 2 Meeting with FDA on Efzofitimod for the Treatment of Pulmonary Sarcoidosis

GlobeNewswire March 10, 2022

aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire March 8, 2022

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2021 Financial Results

GlobeNewswire March 7, 2022

aTyr Pharma to Present at Upcoming Investor Conferences in March

GlobeNewswire March 3, 2022

aTyr Pharma to Participate in Panel at National Institutes of Health Rare Disease Day®

GlobeNewswire February 23, 2022

aTyr Pharma to Present at BIO CEO & Investor Conference

GlobeNewswire February 7, 2022

 aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of "efzofitimod" as Nonproprietary Name

GlobeNewswire January 13, 2022

aTyr Pharma Announces FDA Orphan Drug Designation for ATYR1923 for Treatment of Sarcoidosis

GlobeNewswire January 6, 2022

aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference

GlobeNewswire January 4, 2022

aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources

GlobeNewswire December 24, 2021

aTyr Pharma to Present at Antibody Engineering & Therapeutics Conference

GlobeNewswire December 10, 2021

aTyr Pharma and FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement for aTyr's Lead Therapeutic Candidate ATYR1923

GlobeNewswire November 30, 2021

aTyr Pharma to Present at Upcoming Investor Conferences in November

GlobeNewswire November 12, 2021

aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update

GlobeNewswire November 10, 2021

aTyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, ATYR2810, on Tumor Associated Macrophages at the Society for Immunotherapy of Cancer Annual Meeting

GlobeNewswire November 9, 2021

aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial Results

GlobeNewswire November 3, 2021